Research Topics
Genomes and Genes | Sanjay KaulSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Rosiglitazone and cardiovascular riskSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Curr Atheroscler Rep 10:398-404. 2008..We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive...- ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progressionSanjay Kaul
Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
Curr Drug Targets Cardiovasc Haematol Disord 5:471-9. 2005..These promising data provide the rationale for the development of reconstituted HDL utilizing recombinant apoA-IM as a potential therapeutic approach for atherothrombotic vascular disease in humans... - Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trialsSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
Prog Cardiovasc Dis 49:284-99. 2007.... - Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteriesSanjay Kaul
Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, Calif 90048, USA
Circulation 107:2551-4. 2003.... 
Trial and error. How to avoid commonly encountered limitations of published clinical trialsSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048 1804, USA
J Am Coll Cardiol 55:415-27. 2010..Accordingly, this review highlights these limitations using numerous examples of published clinical trials and describes ways to overcome these limitations, thereby improving the interpretability of research findings...- Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validatedSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center, University of California, Los Angeles, California 90048, USA
J Am Coll Cardiol 48:914-23. 2006..This review outlines the metabolism and pathophysiology of homocysteine, highlights the results of homocysteine observational and interventional trials, and presents areas of uncertainty and potential future work... - Current status and future trends in drug-eluting stentsSanjay Kaul
Division of Cardiology, Cedars-Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
Am Heart Hosp J 5:165-8. 2007 - Good enough: a primer on the analysis and interpretation of noninferiority trialsSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
Ann Intern Med 145:62-9. 2006.... - Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complexSanjay Kaul
Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Am Coll Cardiol 44:1311-9. 2004.... - Trials and tribulations of non-inferiority: the ximelagatran experienceSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
J Am Coll Cardiol 46:1986-95. 2005..Such determinations of non-inferiority are highly dependent on the underlying assumptions, and graphical sensitivity analyses make this dependence explicit... - As time goes by: current status and future directions in the controversy over stentingSanjay Kaul
Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
J Am Coll Cardiol 50:128-37. 2007.... - Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaBS Kaul
Burns and Allen Research Institute and the Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Am Coll Cardiol 35:493-501. 2000..To examine the effect of a polymeric-based periadventitial delivery of a nitric oxide (NO)-releasing diazeniumdiolate, spermine/NO (SPER/NO), on balloon injury-induced neointimal hyperplasia in rat ileofemoral arteries... - Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?S Kaul
Department of Medicine, Cedars Sinai Medical Center, and UCLA School of Medicine, Los Angeles, California 90048, USA
J Am Coll Cardiol 35:1699-712. 2000..The logistic ease of administration without the need for monitoring anticoagulation appears to be the major advantage over UFH... - Advances in antiplatelet treatment for acute coronary syndromesShervin Eshaghian
Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
Heart 96:656-61. 2010.... - Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosisVladimir Rukshin
Department of Medicine, Cedars-Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA
J Cardiovasc Pharmacol 41:615-24. 2003..Thus, tirofiban produced a dose-dependent dethrombotic effect on stent thrombosis and inhibited acute de novo stent thrombosis under high-shear flow conditions... - A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent implantationVladimir Rukshin
Burns and Allen Research Institute, Department of Medicine, Cedars-Sinai Medical Center, and UCLA School of Medicine, Los Angeles, California, USA
J Cardiovasc Pharmacol Ther 8:193-200. 2003..A randomized clinical trial comparing magnesium with glycoprotein inhibitors during percutaneous coronary intervention is warranted... - Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null miceXiaojun Li
Atherosclerosis Research Center, Division of Cardiology, Department of Medicine and Burns and Allen Research Institute, Cedars-Sinai Medical Center and David Geffen School of Medicine at UCLA, Los Angeles, Calif 90048, USA
Circulation 110:1701-5. 2004..These observations suggest that the type of atherosclerotic lesions and the time of initiation during the course of lesion evolution modulate the beneficial effects of apoA-I-mimetic peptides on atherosclerosis... - Role of clopidogrel in managing atherothrombotic cardiovascular diseaseShervin Eshaghian
Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
Ann Intern Med 146:434-41. 2007.... - An orwellian discourse on the meaning and measurement of noninferiorityGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
Am J Cardiol 99:284-7. 2007..In conclusion, the resultant probabilistic measures thereby render the meaning of noninferiority more transparent and clinically relevant... - Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoproteinSimcha Ron Meisel
Atherosclerosis Research Center, Division of Cardiology, Department of Medicine, The CSMC Burns and Allen Research Institute
J Atheroscler Thromb 18:596-603. 2011..In this study we tested the hypothesis that oxLDL modulates TF expression in human monocyte-derived macrophages (MDMs)... - The JUPITER trial: myth or reality?Ryan P Morrissey
Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Curr Atheroscler Rep 13:413-21. 2011..Given these limitations, the attendant societal health policy implications remain largely unknown... - Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosisVladimir Rukshin
Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, Los Angeles, Calif, USA
Circulation 105:1970-5. 2002..Its potential use in percutaneous coronary intervention requires further study... - Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular deathGeorge A Diamond
Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
Ann Intern Med 147:578-81. 2007..We conclude that the risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone is uncertain: Neither increased nor decreased risk is established... - Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidenceRoderick Tung
Cedars-Sinai Medical Center, David Geffen School of Medicine, and University of California, Los Angeles, Los Angeles, California 90048, USA
Ann Intern Med 144:913-9. 2006.... - Bridging therapy in the perioperative management of patients with drug-eluting stentsStanley Chou
Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, CA, USA
Rev Cardiovasc Med 10:209-18. 2009.... - Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDLX H Xu
Atherosclerosis Research Center, Burns and Allen Research Institute, Division of Cardiology, Steven Spielberg Pediatric Research Center, Los Angeles, California, USA
Circulation 104:3103-8. 2001..Moreover, upregulation of TLR-4 in macrophages by oxidized LDL suggests that TLR-4 may provide a potential pathophysiological link between lipids and infection/inflammation and atherosclerosis... - Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient miceP K Shah
Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, Calif 90048, USA
Circulation 97:780-5. 1998..In this study, we tested the hypothesis that apo A-I(Milano)/PC would inhibit aortic atherosclerosis in apo E-deficient mice... - COURAGE under fire: on the management of stable coronary diseaseGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California, USA
J Am Coll Cardiol 50:1604-9. 2007..We herein reevaluate the evidence with regard to each of these points, and conclude that COURAGE indeed provides relevant new information to assist the practitioner in the appropriate management of patients with stable coronary disease... - Cardiac amyloidosis: new insights into diagnosis and managementShervin Eshaghian
Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
Rev Cardiovasc Med 8:189-99. 2007..Recent advances in our understanding of the pathophysiology of amyloid have allowed the various types to be differentiated, which has led to targeted therapy for each unique pathophysiologic process... - Acute myocardial infarction in human immunodeficiency virus-infected patientsShlomo Matetzky
Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
Arch Intern Med 163:457-60. 2003..Although HIV-infected patients have a higher incidence of postdischarge ischemic events, restenosis, and stent thrombosis, the intermediate-term mortality is low... - Bayesian classification of clinical practice guidelinesGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Arch Intern Med 169:1431-5. 2009..We conclude that this quantitative schema has the potential to improve the quality and cost of evidence-based clinical management... - Statins in acute coronary syndromes: do the guideline recommendations match the evidence?Ryan P Morrissey
Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Am Coll Cardiol 54:1425-33. 2009..On the basis of these observations, and despite a compelling pathophysiologic rationale, the justification for current Class I, Level of Evidence: A recommendation for statin therapy in patients with ACS remains open to question... - The things to come of SHAPE: cost and effectiveness of cardiovascular preventionGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
Am J Cardiol 99:1013-5. 2007..In conclusion, greater attention should be paid to improving the population-wide delivery of and long-term adherence to proven preventive therapy than to the identification of "high-risk" treatment targets... - Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrialsGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, and the School of Medicine, University of California, Los Angeles, California, USA
J Am Coll Cardiol 43:1929-39. 2004..Accordingly, the Bayesian approach should be employed more widely in the design, analysis, and interpretation of clinical megatrials... - Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt studyYoram Neuman
Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars-Sinai Medical Center, Division of Cardiology, Room 5314, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Thromb Res 112:99-104. 2003..These findings suggest the potential of ultrasound as an adjunct to antithrombotic therapy to improve effectiveness without increasing the risk of bleeding complications during treatment of vascular thrombosis... - Screen testing cardiovascular prevention in asymptomatic diabetic patientsGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
J Am Coll Cardiol 49:1915-7. 2007..This analysis shows that unconditional treatment is the dominant strategy, costing 24% less ($3.2 billion) and preventing 25% more (16,800) atherosclerotic events annually on a national basis... - Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt studyS Kaul
Division of Cardiology, Cedars Sinai Medical Center Research Institute, Los Angeles, CA, USA
Circulation 94:2228-34. 1996..The objective of the present study was to determine whether local delivery of a new type of NO donor, the NO adduct of N,N'-dimethylhexanediamine (DMHD/NO), inhibits acute stent thrombosis (ST) at high-shear flow... - Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout miceK Y Chyu
Atherosclerosis Research Center, Burns and Allen Research Institute, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles CA 90048, USA
Circ Res 85:1192-8. 1999..Taken together, these findings suggest that iNOS expression after vascular injury may promote neointima formation... - High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilizationP K Shah
Atherosclerosis Research Center, The Division of Cardiology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, Calif and Esperion Therapeutics Inc, Ann Arbor, Michigan, USA
Circulation 103:3047-50. 2001..In this study, we tested whether a single high dose of recombinant apoA-I(m) could rapidly mobilize tissue cholesterol and reduce plaque lipid and macrophage content in apoE-deficient mice... - Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediatorsT B Rajavashisth
Atherosclerosis Research Center, Burns and Allen Research Institute, Division of Cardiology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
Circulation 99:3103-9. 1999.... - Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricleMoshe Swissa
Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles 90048, USA
Am J Physiol Heart Circ Physiol 282:H1787-92. 2002..We conclude that a sildenafil (2 microg/ml) and NO donor combination increases VT/VF vulnerability in the normal RV by a mechanism compatible with the restitution hypothesis... - Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trialsTong Liu
The Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Heart 97:1034-40. 2011..Previous randomised controlled trials (RCT) regarding n-3 PUFA supplementation for atrial fibrillation (AF) prevention have yielded conflicting results... - From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic eventsGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, Calif, USA
Am J Med 120:5-11. 2007.... - Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?David Singh
Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
J Am Coll Cardiol 55:1569-76. 2010..We conclude that the available data support the use of dronedarone in select patient populations as a second- or third-line agent... - Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activitySimcha R Meisel
Department of Medicine, Atherosclerosis Research Center, Division of Cardiology, The Cedars Sinai Medical Center Burns and Allen Research Institute, School of Medicine, University of California, Los Angeles, CA, USA
Atherosclerosis 161:35-43. 2002..This cell-culture model may provide the opportunity to evaluate the effect of various interventions on macrophage procoagulant activity... - Hazardous to your health: kinetic foundations of risk stratification and therapeutic triageGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, USA
Am J Med 119:275.e1-6. 2006..Clinical risk stratification nevertheless relies only on the former... - Forbidden fruit: on the analysis of recurrent events in randomized clinical trialsGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
Am J Cardiol 111:1530-6. 2013..The application of this approach to several previously published trials illustrates its facility to help elucidate the causal mechanisms underlying empirical demonstrations of safety and efficacy... - On reporting of effect size in randomized clinical trialsGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center and University of California, Los Angeles, California, USA
Am J Cardiol 111:613-7. 2013..In conclusion, our results have shown that composite measures of effect size communicate the clinical importance of trial results better than do conventional assessments of risk reduction and statistical significance... - By desperate appliance relieved? On the clinical relevance of risk stratification to therapeutic decision-makingGeorge A Diamond
Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California
Am J Cardiol 109:919-23. 2012..Instead, risk stratification guidelines specific to a particular disease and a particular treatment should be founded on prospective empiric validation... - Intravenous magnesium in experimental stent thrombosis in swineV Rukshin
Thrombosis Research Laboratory of the Atherosclerosis Research Center, Burns and Allen Research Institute, Div. of Cardiology, Dept. of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, USA
Arterioscler Thromb Vasc Biol 21:1544-9. 2001..Thus, magnesium may be an effective agent for preventing stent thrombosis... - Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patientsM Shechter
Cedars Sinai Burns and Allen Research Institute, Department of Medicine, Cedars Sinai Medical Center and the UCLA School of Medicine Los Angeles, California, USA
Magnes Res 13:275-84. 2000..These findings suggest a potential mechanism whereby magnesium may beneficially alter outcomes in patients with CAD... - Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidenceS Dhar
Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
Postgrad Med J 85:299-302. 2009..We review the role of natriuretic peptide in heart failure in the setting of chronic renal disease... - Rosiglitazone and cardiovascular riskGeorge A Diamond
N Engl J Med 357:938-9; author reply 939-40. 2007 - From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part IMorteza Naghavi
The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
Circulation 108:1664-72. 2003..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients... - From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part IIMorteza Naghavi
The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
Circulation 108:1772-8. 2003..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients... - From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force reportMorteza Naghavi
Association for Eradication of Heart Attack, Houston, Texas 77005, USA
Am J Cardiol 98:2H-15H. 2006.... - Revascularization for unprotected left main stem coronary artery stenosis stenting or surgeryDavid P Taggart
Department of Cardiac Surgery, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
J Am Coll Cardiol 51:885-92. 2008..We conclude that CABG should indeed remain the preferred revascularization treatment in good surgical candidates with unprotected LMS stenosis... - Effect of exposure to cigarette smoke on carotid artery intimal thickening: the role of inducible NO synthaseTakeo Anazawa
Division of Cardiology and Atherosclerosis Research Center, Burns and Allen Research Institute, and the Department of Medicine, Cedars Sinai Medical Center and David Geffen School of Medicine at University of California, Los Angeles 90048, USA
Arterioscler Thromb Vasc Biol 24:1652-8. 2004..We investigated the role of inducible NO synthase (iNOS) in intimal thickening with exposure to cigarette smoke (CS)... - Simvastatin with or without ezetimibe in familial hypercholesterolemiaGeorge A Diamond
N Engl J Med 359:530; author reply 532. 2008